Skip to main content
Premium Trial:

Request an Annual Quote

Marina Presents Data on Target Knockdown in Malignant Ascites Model


Marina Biotech this week released data showing that its proprietary RNAi molecules delivered with an in-house liposome delivery vehicle could be used to knock down target mRNA levels in an orthotopic model of malignant ascites.

“Malignant ascites, also known as malignancy-related ascites, is a condition in which fluid collects in the abdomen as a result of cancer,” commonly ovarian and gastrointestinal cancers, according to the company.

Intraperitoneal administration of the company's UsiRNAs targeting the oncogene polo-like kinase 1 formulated with the firm's so-called DiLA2 delivery system led to as much as 90 percent knockdown of PLK1 mRNA in ovarian cancer-derived tumor tissue through a confirmed RNAi effect.

"These results further demonstrate the utility of our DiLA2 delivery technology for local administration," Marina CSO Barry Polisky said in a statement. "As we look to expand our preclinical and clinical pipeline, malignant-related ascites is an ideal pipeline opportunity for us. ... We believe we can rapidly develop clinical candidates for IND-enabling studies should our preclinical efforts continue to demonstrate positive results."

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.